Abstract
| Original language | English |
|---|---|
| Title of host publication | The Biology and Therapeutic Application of Mesenchymal Cells |
| Place of Publication | Hoboken, New Jersey |
| Publisher | John Wiley & Sons |
| Chapter | 51 |
| Pages | 754-769 |
| Number of pages | 16 |
| ISBN (Electronic) | 9781118907375, 9781118907290 |
| ISBN (Print) | 9781118907511 |
| Publication status | Published - 2017 |
Cite this
}
Mesenchymal stromal cells targeting kidney disease : Benefits of a combined therapeutic approach. / Huuskes, Brooke M.; Ricardo, Sharon D.
The Biology and Therapeutic Application of Mesenchymal Cells. Hoboken, New Jersey : John Wiley & Sons, 2017. p. 754-769.Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review
TY - CHAP
T1 - Mesenchymal stromal cells targeting kidney disease
T2 - Benefits of a combined therapeutic approach
AU - Huuskes, Brooke M.
AU - Ricardo, Sharon D.
PY - 2017
Y1 - 2017
N2 - Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.
AB - Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.
UR - https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118907474.ch51
M3 - Chapter (Book)
SN - 9781118907511
SP - 754
EP - 769
BT - The Biology and Therapeutic Application of Mesenchymal Cells
PB - John Wiley & Sons
CY - Hoboken, New Jersey
ER -